Click here for an archive of Cramer's "Mad Money" recaps.
Jim Cramer told viewers of his "Mad Money" TV show Monday that he has done an about-face on
and is now bullish.
NitroMed, which Cramer recommended selling into hype this summer after BiDil, the company's treatment for congestive heart failure in African-Americans was approved by the FDA, is now too disliked, he said.
About one-third of the company's float has been sold short, which is "staggering," said Cramer. The stock has dropped from about $24 in July to $16.76 as of Monday's close. The bears are now being piggish, said Cramer.
Wall Street is expecting $200 million to $250 million in revenue from BiDil in 2008. But a survey released Monday evening finds BiDil is likely to have revenue of $637 million. That's a huge difference, said Cramer.
Also, the drug, which had been getting about 50 to 70 prescriptions a day, is now seeing 300 to 400 prescriptions a day, according to the latest data.
"BiDil doesn't need to do well for NitroMed to make you a lot of money," said Cramer. "It just needs to do better, and that's exactly what I see happening."
Cramer is bullish on
(HAIN - Get Report)
after reading a story last week in
about how the level of pesticides in children fell dramatically once the children began eating organic food.
Sales of organic baby food are up 57% over the past four years, said Cramer. Hain's line of organic baby food, Earth's Best, grew 23% last year, he said. Hain's organic baby food is sold in
Whole Foods Market
Wild Oats Market
Hain is a great way to have some food exposure, said Cramer. Also, the holiday season historically has been the best-performing period for Hain's stock each year.